Summit Therapeutics Inc.
SMMT NASDAQHealthcare ★★★★★Latest Earnings
Date
Jul 23, 2026
ET
EPS Est.
-0.27
EPS Actual
-0.28
Revenue Est.
$113889
Revenue Actual
--
Next Earnings Report Date unconfirmed
Date
Oct 19, 2026 · Mon
Time
Time TBD
Fiscal Period
--
EPS Est.
-0.28
Revenue Est.
$71429
Company Overview
Summit Therapeutics Inc. (ticker SMMT) is listed on NASDAQ with a market cap of about $10.5B. Its next earnings report is expected on Oct 19, 2026 (ET), Time TBD (date pending company confirmation), with consensus EPS of -0.28. In the last 11 reported quarters, EPS beat consensus estimates 5 times.
Actual EPS TrendRecently15Term · Mar 9, 2023 → Jul 23, 2026
Mar 9, 2023Range: -0.76 ~ -0.02Jul 23, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 23, 2026 | -- | -0.27 | -0.28 | $113889 | -- |
| Apr 30, 2026 | -- | -0.33 | Above forecast↑-0.24 | $54420 | -- |
| Feb 23, 2026 | -- | -0.10 | Below forecast↓-0.29 | $56.8M | -- |
| Oct 20, 2025 | -- | -0.18 | Below forecast↓-0.31 | $76.5M | -- |
| Aug 11, 2025 | -- | -0.09 | Below forecast↓-0.76 | -- | -- |
| May 1, 2025 | -- | -0.09 | -0.09 | -- | -- |
| Feb 24, 2025 | -- | -0.08 | -0.08 | -- | -- |
| Oct 30, 2024 | -- | -0.07 | -0.08 | -- | -- |
| Aug 6, 2024 | -- | -0.06 | Above forecast↑-0.05 | -- | -- |
| May 1, 2024 | -- | -0.06 | -0.06 | -- | -- |
| Feb 20, 2024 | -- | -- | -0.04 | -- | -- |
| Nov 7, 2023 | -- | -- | -0.03 | -- | -- |
| Aug 9, 2023 | -- | -- | -0.02 | -- | $235000 |
| May 11, 2023 | -- | -- | -0.06 | -- | -- |
| Mar 9, 2023 | -- | -0.26 | Above forecast↑-0.07 | -- | $705 |
Original Filings (SEC)
8-K2026-08-05 ↗
8-K2026-07-23 ↗
10-Q2026-07-23 ↗
8-K2026-07-23 ↗
8-K2026-07-22 ↗
8-K2026-06-12 ↗
8-K2026-06-11 ↗
8-K2026-06-03 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
